References: Direct-acting oral anticoagulants for VTE treatment

  • Ageno W, Mantovani LG, Haas S, Kreutz R, Monje D, Schneider J, et al. Safety and effectiveness of oral rivaroxaban versus standard anticoagulation for the treatment of symptomatic deep-vein thrombosis (XALIA): an international, prospective, non-interventional study. Lancet Haematol 2016;3(1):e12-21. https://www.ncbi.nlm.nih.gov/pubmed/26765643
  • Beyer-Westendorf J, Marten S. Reproductive issues in women on direct oral anticoagulants. Res Pract Thromb Haemost 2021;5(4):e12512. https://www.ncbi.nlm.nih.gov/pubmed/33977211
  • Prins MH, Lensing AW, Brighton TA, Lyons RM, Rehm J, Trajanovic M, et al. Oral rivaroxaban versus enoxaparin with vitamin K antagonist for the treatment of symptomatic venous thromboembolism in patients with cancer (EINSTEIN-DVT and EINSTEIN-PE): a pooled subgroup analysis of two randomised controlled trials. Lancet Haematol 2014;1(1):e37-46. https://www.ncbi.nlm.nih.gov/pubmed/27030066